TY - JOUR
T1 - Treatment of osteoporosis after hip fracture is associated with lower all-cause mortality
T2 - A nationwide population study
AU - Tai, Ta Wei
AU - Li, Chia Chun
AU - Huang, Chun Feng
AU - Chan, Wing P.
AU - Wu, Chih Hsing
N1 - Funding Information:
We are grateful to the Health Data Science Center, National Cheng Kung University Hospital for providing administrative and technical support. This work was partially supported by a research grant from the Taiwanese Osteoporosis Association, Taiwan.
Funding Information:
This work was partially supported by a research grant from the Taiwanese Osteoporosis Association, Taiwan .
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2022/1
Y1 - 2022/1
N2 - Purpose: Mortality after osteoporotic hip fractures is high. Postoperative care is as important as surgery itself to prevent a second fracture and improve outcomes, and the effect of anti-osteoporosis treatment after hip fractures on overall mortality is controversial. This nationwide population study aimed to determine whether anti-osteoporosis treatment might reduce overall mortality after hip fracture surgery. Methods: We conducted this cohort study using the National Health Insurance Research Database (NHIRD) of Taiwan to identify patients admitted for surgery due to hip fractures from 2008 to 2018. The subsequent use and duration of anti-osteoporotic medication and other parameters were analyzed, and national death registration records were retrieved to investigate mortality. Results: A total of 59,943 patients admitted for hip fracture surgery were identified. The 22,494 patients (37.5%) who received anti-osteoporotic medication showed a lower all-cause mortality rate compared with the 37,449 patients (62.5%) who did not receive further treatment (hazard ratio (HR): 0.69, 95% confidence interval (CI): 0.67–0.70, p < 0.0001). Patients who received anti-osteoporotic medication for more than 1, 2, and 3 years exhibited propotional reductions in all-cause mortality (HR & 95%CI: 0.57 (0.54–0.60), 0.42 (0.38–0.46), and 0.29 (0.26–0.33) respectively). Conclusion: Anti-osteoporosis treatment was associated with lower all-cause mortality after hip fracture surgery. A longer duration of treatment was also associated with lower mortality. Postoperative treatment for osteoporosis is crucial for patients with hip fracture.
AB - Purpose: Mortality after osteoporotic hip fractures is high. Postoperative care is as important as surgery itself to prevent a second fracture and improve outcomes, and the effect of anti-osteoporosis treatment after hip fractures on overall mortality is controversial. This nationwide population study aimed to determine whether anti-osteoporosis treatment might reduce overall mortality after hip fracture surgery. Methods: We conducted this cohort study using the National Health Insurance Research Database (NHIRD) of Taiwan to identify patients admitted for surgery due to hip fractures from 2008 to 2018. The subsequent use and duration of anti-osteoporotic medication and other parameters were analyzed, and national death registration records were retrieved to investigate mortality. Results: A total of 59,943 patients admitted for hip fracture surgery were identified. The 22,494 patients (37.5%) who received anti-osteoporotic medication showed a lower all-cause mortality rate compared with the 37,449 patients (62.5%) who did not receive further treatment (hazard ratio (HR): 0.69, 95% confidence interval (CI): 0.67–0.70, p < 0.0001). Patients who received anti-osteoporotic medication for more than 1, 2, and 3 years exhibited propotional reductions in all-cause mortality (HR & 95%CI: 0.57 (0.54–0.60), 0.42 (0.38–0.46), and 0.29 (0.26–0.33) respectively). Conclusion: Anti-osteoporosis treatment was associated with lower all-cause mortality after hip fracture surgery. A longer duration of treatment was also associated with lower mortality. Postoperative treatment for osteoporosis is crucial for patients with hip fracture.
KW - Hip fracture
KW - Mortality
KW - Osteoporosis
UR - http://www.scopus.com/inward/record.url?scp=85115908569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115908569&partnerID=8YFLogxK
U2 - 10.1016/j.bone.2021.116216
DO - 10.1016/j.bone.2021.116216
M3 - Article
C2 - 34571203
AN - SCOPUS:85115908569
SN - 8756-3282
VL - 154
JO - Bone
JF - Bone
M1 - 116216
ER -